Highest-materiality recent filing
Rani Therapeutics appoints Nicholas Maestas as CFO, approves 2026 Equity Inducement Plan
Nicholas Maestas appointed CFO effective June 29, 2026, succeeding Svai Sanford.
Rani Therapeutics raises $20M via common stock and pre-funded warrant offering
Issues 12.48M shares at $1.07/share and pre-funded warrants for 6.21M shares at $1.0699.
Rani Therapeutics Q1 net loss narrows to $8M; Nasdaq bid price non-compliance; CFO to depart
Q1 net loss $8.0M, narrowed from $12.7M YoY; cash $43.4M expected to fund operations into Q4 2027.
Collaboration with Chugai for up to $1.085B to develop oral therapy using RaniPill; Chugai may expand to 5 additional targets.
Entered collaboration with Chugai for oral therapy using RaniPill platform; potential total value up to $1.085B including options for up to five additional targets.
Rani Therapeutics closes private placement of 42.6M shares and warrants; board changes
Closed private placement of 42,633,337 shares of Class A common stock, warrants to purchase 125,000,004 shares, and pre-funded warrants for 82,366,667 shares.
Rani raises $60.3M, partners with Chugai on hemophilia drug via RaniPill
Private placement: ~$60.3M gross from 42.6M shares and warrants at $0.48/share (institutional) and $0.605 (affiliate).
Rani Therapeutics Q2 net loss $11.2M, cash at $10.2M; collaboration with Chugai announced
Net loss of $11.2M for Q2 2025 vs $13.4M in Q2 2024; includes $3.3M stock-based compensation.
Rani Therapeutics receives Nasdaq bid price deficiency notice; 180-day cure ends Dec 17
Received Nasdaq notice on June 20, 2025 for non-compliance with $1.00 minimum bid price (30 consecutive business days below $1.00).
Rani Therapeutics induces warrant exercise by Armistice, receives ~$4.3M
Gross proceeds of ~$4.3M from cash exercise of Series B & C warrants at reduced exercise price of $0.65/sh.
Rani Therapeutics Q1 net loss $12.7M, cash $15.9M; RT-114 Phase 1 mid-2025
Net loss was $12.7M for Q1 2025 ($14.8M in Q1 2024); cash, equivalents and marketable securities fell to $15.9M from $27.6M at year-end.
Rani Therapeutics receives Nasdaq deficiency notice for MVLS below $50M
Nasdaq notified Rani on May 1, 2025 that its Market Value of Listed Securities was below $50M for 30 consecutive business days.
Rani Therapeutics auditor Marcum resigns; FY2024 report had going concern note
Marcum resigned as independent auditor on April 7, 2025; Audit Committee accepted resignation.
FY2024 net loss of $56.6M vs $67.9M in 2023; cash and marketable securities $27.6M, expected to fund operations into Q3 2025.
Rani Therapeutics Q3 net loss $12.7M; cash $30.4M extended into Q3 2025
Net loss of $12.7M for Q3 2024, compared to $18.3M in Q3 2023; includes $4.1M stock-based comp.
Rani Therapeutics to raise ~$10M via stock/warrant offering; cancels prior warrants
Issuing 3M shares + pre-funded warrants for 333K shares + Series C warrants for 3.33M shares at $3.00 combined price.
Rani Therapeutics dismisses EY as auditor, appoints Marcum; EY's 2023 report had going concern doubt
EY dismissed as independent auditor on Sep 10, 2024; Marcum LLP appointed immediately.
Cash, equivalents and marketable securities totaled $30.9M as of June 30, 2024, down from $48.5M at Dec. 31, 2023.
Rani Therapeutics decides not to pursue equity financing after investor talks
Engaged in discussions with investors for a potential equity financing but elected not to proceed.
Parties will share development costs and operating profits/losses equally; Rani leads US, Canada, Europe, Australia development after Phase 2.
Rani Therapeutics FY2023 net loss $67.9M; cash $48.5M; positive Phase 1 for RT-111 oral antibody
Net loss for FY2023 was $67.9M ($63.3M in 2022); cash and equivalents $48.5M (down from $98.5M at year-end 2022).
Rani announces positive Phase 1 topline results for oral ustekinumab biosimilar RT-111
RT-111 achieved 84% bioavailability vs subcutaneous Stelara injection; higher Cmax and shorter Tmax observed.
Rani Therapeutics reprices stock options for executives to $2.84 per share
Board approved reducing exercise price of certain outstanding options to $2.84 per share (closing price on Dec 16, 2023).
Rani Therapeutics Q3 net loss $18.3M, cash $60.5M, CEO salary cut to $100k, workforce reduced 25%
Net loss $18.3M in Q3 2023 vs $16.2M in Q3 2022; R&D spend $11.2M, cash burn extends runway into 2025.
Workforce reduced ~25%; restructuring cost ~$0.3M (nearly all cash) expected Q4 2023, complete by Q1 2024.
Rani Therapeutics reports positive preclinical safety data for RaniPill capsule in 60-day GLP study
60-day repeat administration in healthy animals showed no treatment-related adverse events; all animals remained healthy.
Rani Therapeutics Q2 2023 net loss $18.7M; cash $74.6M; expands Celltrion partnership
Net loss of $18.7M for Q2 2023, up from $16.0M in Q2 2022; cash and securities $74.6M (down from $98.5M at YE 2022).
Rani Therapeutics Q1 net loss $16.8M; Celltrion partnership and FDA feedback on RT-102
Net loss of $16.8M for Q1 2023, up from $13.8M in Q1 2022; non-cash stock compensation $4.0M.
Rani Therapeutics reports FY2022 net loss $63.3M; cash $98.5M; RT-102 Phase 2 in H2 2023
Net loss $63.3M for 2022, vs $53.1M in 2021; cash $98.5M, sufficient to mid-2024.
Preliminary cash, cash equivalents, restricted cash equivalents and marketable securities of ~$99M as of Dec 31, 2022, subject to audit.
No serious adverse events; all 10 participants completed 7-day daily dosing.
Rani Therapeutics Q3 2022 net loss $16.2M; cash $98.7M; pipeline progress highlighted
Cash, cash equivalents, restricted cash equivalents and marketable securities totaled $98.7M at Sept 30, 2022, down from $117.5M at Dec 31, 2021.
Preclinical development started for RT-111, an oral ustekinumab biosimilar for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Rani Therapeutics enters $150M ATM equity offering agreement with Cantor and H.C. Wainwright
Up to $150M of Class A common stock may be sold at market prices on Nasdaq through agents Cantor Fitzgerald and H.C. Wainwright.
Rani Therapeutics Q2 net loss $16M; positive RT-102 Phase 1 results
Positive Phase 1 topline results for RT-102 (PTH capsule for osteoporosis): high bioavailability, well-tolerated, all endpoints met.
On May 12, 2026, Svai Sanford, the Company’s Chief Financial Officer, advised the Company that he will resign from his position following the appointment of his successor.
On April 24, 2025, Laureen DeBuono notified the Board of Directors (“Board”) of Rani Therapeutics Holdings, Inc. (the “Company”) that she has decided to retire from the Board effective immediately.
On March 30, 2023, Ms. Lyn Baranowski notified Rani Therapeutics Holdings, Inc. (the “Company”) that she does not intend to stand for re-election at the 2023 annual meeting of stockholders of the Company (“Annual Meeting”).
On January 2, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the board of directors (the “Board”) of Rani Therapeutics Holdings, Inc. (the “Company”) elected Lisa Rometty as a director of the Company, effective January 3, 2022, with a term expiring at the Company’s next annual meeting of stockholders.
On November 10, 2021, upon the recommendation of its Nominating and Corporate Governance Committee, the board of directors (the “Board”) of Rani Therapeutics Holdings, Inc. (the “Company”) elected Lyn Baranowski as a Director, effective immediately, with a term expiring at the Company’s next annual meeting of stockholders.
Max materiality 0.90 · Median 0.65 · Most common event other_material